Survival Is Poorer in Patients With Secondary Core-binding Factor Acute Myelogenous Leukemia Compared With De Novo Core-binding Factor Leukemia.

The article presents a study which compares the overall survival (OS) rate to patients with secondary core-binding factor acute myelogenous leukemia (CBF AML) compared to patients with de novo CBF AML. Result shows that patients with secondary CBF AML were found to have worse overall (OS) compared to patients with de novo CBF AML. The secondary CBF AML status appeared to have marginal significance in multivariate analysis that indicates worse OS and event-free survival (EFS).